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Abstract
Background: Current smokers have an increased cardiovascular disease (CVD) risk compared to ex-smokers due to
reversible as well as irreversible effects of smoking. We investigated if current smokers remain to have an increased CVD risk
compared to ex-smokers in subjects with a long and intense smoking history. We in addition studied if the effect of smoking
continuation on CVD risk is independent of or modified by the presence of cardiovascular calcifications.
Methods: The cohort used comprised a sample of 3559 male lung cancer screening trial participants. We conducted a case-
cohort study using all CVD cases and a random sample of 10% (n = 341) from the baseline cohort (subcohort). A weighted
Cox proportional hazards model was used to estimate the hazard ratios for current smoking status in relation to CVD events.
Results: During a median follow-up of 2.6 years (max. 3.7 years), 263 fatal and non-fatal cardiovascular events (cases) were
identified. Age, packyears and cardiovascular calcification adjusted hazard ratio of current smokers compared to former
smokers was 1.33 (95% confidence interval 1.00–1.77). In additional analyses that incorporated multiplicative interaction
terms, neither coronary nor aortic calcifications modified the association between smoking status and cardiovascular risk
(P = 0.08).
Conclusions: Current smokers have an increased CVD risk compared to former smokers even in subjects with a long and
intense smoking history. Smoking exerts its hazardous effects on CVD risk by pathways partly independent of cardiovascular
calcifications.
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Introduction
Cardiovascular disease (CVD) is one of the major causes of
death worldwide. As many as 30% of the deaths from CVD are
attributed to cigarette smoking [1,2]. Previous studies have
consistently demonstrated that smoking cessation rapidly and
markedly reduces coronary heart disease (CHD) risk [3,4]. One
year after quitting, the risk of CHD decreases by 50 percent,
indicating that certain mechanisms by which smoking induces
CVD are reversible to some extent [5–7]. However, smoking also
has irreversible effects, by which former smokers continue to have
an elevated CVD risk for a long time, even years after they have
quit smoking [8–10]. Subsequently, it could be hypothesized that
the advantageous effect of smoking cessation on CVD risk may be
attenuated in subjects with an extended and intense smoking
history. So, we aim to investigate if in a population containing
subjects who have a common long and intense smoking history
current smokers have a different CVD risk compared to ex-
smokers. Furthermore, smoking is associated with coronary and
aortic calcifications. These calcifications play an important role in
plaque vulnerability which is considered to cause an increased
CVD risk [8–10]. We, in addition, intend to investigate whether
the relation between current smoking status and CVD risk is
independent of, or modified by, cardiovascular calcifications.
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Materials and Methods
Study Population
This is an ancillary study of the Dutch and Belgian Lung
Cancer Screening Trial (NELSON trial; ISRCTN63545820) [11].
NELSON was approved by the Dutch and Belgian Ministry of
Health and by the ethical review board of the participating
hospitals. Written informed consent was obtained from each
participant. The trial population comprised subjects between the
ages of 50 and 75 years with a smoking history of .15 cigarettes a
day for.25 years or.10 cigarettes a day for.30 years, and who
were current smokers, or former smokers who quit smoking
,10 years ago. Exclusion criteria for participating in the lung
cancer screening trial were self-reported moderate or poor health
with inability to climb two flights of stairs, recent chest CT, current
or previous history of cancer, and body weight $140 kg. At
baseline, participants in the NELSON-trial filled in a question-
naire regarding their current smoking behavior and the number of
pack years smoked. A pack year is defined as twenty cigarettes
smoked everyday for one year. Subjects who were active smokers
at the time of scanning were classified as current smokers [11].
Sample Selection and Study Design
In the present study, 3559 male participants from two
participating hospitals, University Medical Center in Groningen
(UMCG) and University Medical Center in Utrecht (UMCU),
represent the full cohort and were considered for analyses. We
used a case-cohort design as introduced by Prentice [12], that
consists of cases and a subcohort sample that is randomly sampled
from the full cohort at the beginning of the study. Subjects who
developed a cardiovascular event during follow-up were identified
as cases. We selected a random sample of < 10% (n= 341) from
the full cohort to serve as the subcohort. With sampling fractions
of $0.10, results of a case-cohort analysis are similar to the full
cohort analysis [13]. The cases together with the subcohort define
the actual population under study. The advantage of this design is
that it enables the performance of survival analyses without the
need to score all 3559 chest CT scans.
CT Scanning
Between January 2004 and December 2007 all subjects
underwent a volumetric chest CT in full inspiration. CTs were
obtained without cardiac or respiratory gating on 16-slice MDCT
scanners with a collimation of 1660.75 mm. The participants at
UMCG were scanned on a Sensation-16 CT (Siemens Medical
Solutions, Forchheim, Germany), whereas the participants at
UMCU were scanned on either a Mx8000 or Brilliance-16P CT
(Philips Medical Systems, Cleveland, OH, USA). Exposure settings
were adjusted according to body weight: 80–100 kVp (,50 kg),
120 kVp (50–80 kg) or 140 kVp (80 kg or more) at 30 mAs,
yielding a computed tomography dose index of 0.8, 1.6 and 3.2
mGy, respectively. Axial images with a slice thickness of 1-mm at
0.7-mm increment were reconstructed using a smooth reconstruc-
tion filter (Siemens B30f, Philips B-filter).
Scoring of CT Characteristics
CT scoring was performed at a research workstation (iX
Viewer; Image Sciences Institute). Left anterior descending
coronary artery calcification (CAC) and descending aortic
calcifications (DAC), were scored as previously described
[14,15]. Briefly, calcifications in the left anterior descending
(LAD) were assessed using the following scale; grade 1, mild (1–2
focal [limited to,=2 slices] calcifications); grade 2, moderate (.2
focal calcifications or a single calcification extending for .2 slices);
and grade 3, severe (fully calcified coronary arteries extending over
multiple segments). The lower margin of the descending aorta was
defined as the level from where the diaphragm could be seen. The
number and size of aortic wall calcifications were assessed and
graded as follows: grade 0, absent; grade 1, mild (,=3 focal
calcifications); grade 2, moderate (4–5 focal calcifications or 1
calcification extending for .=3 slices); and grade 3, severe (.5
focal calcifications or .1 calcification extending for .=3 slices).
CT scoring was performed by a research physician with two
years of experience in reading chest CT. The reader was blinded
for participant’s characteristics and outcome status. Adequate
scoring of the chest CT was assessed by evaluating the
reproducibility of the visual grading between the research
physician and an experienced board certified chest radiologist
for a subset of 50 randomly selected chest CTs, that were part of
this study. Weighted kappa’s were 0.85 for CAC and 0.72 for
DAC, reflecting a good interobserver agreement between the
research physician and the chest radiologist.
Follow up and Cardiovascular Events
Data on fatal and non-fatal CVD events were obtained from the
Dutch National Registry of Hospital Discharge Diagnoses and the
National Death Registry from baseline to January 2008. Accord-
ing to the International Classification of Diseases (ICD) the Dutch
National Registry codes all discharge diagnoses as ICD-9 and the
causes of death as ICD-10 codes [16]. The database was linked to
the study cohort with a validated probabilistic method [17,18].
Using the ICD-9 codes, we categorized cardiovascular disease
events (codes 390 to 459) as coronary heart disease (CHD) (codes
410 to 414), including acute myocardial infarction (AMI) (code
410), cerebrovascular disease (codes 430–438) or other cardiovas-
cular disease.
Using the ICD-10 codes, we categorized cardiovascular deaths
(codes I00–I99) as ischemic heart deaths (codes I20–I25),
cerebrovascular death (codes I60–I69) or death due to other
cardiovascular disease.
Whenever multiple events occurred, the first diagnosis was
taken as an end point, aside from cardiovascular deaths, which
prevailed over hospital admissions.
Statistical Analyses
The baseline characteristics of the CVD cases (n = 263) and the
subcohort (n = 341) are presented. Medians and quartile limits
(quartile 1 to 3 [Q1–Q3]) were computed for the continuous
variables, as they all showed skewed distributions. Categorical
variables were expressed as frequencies. The numbers of subject
with moderate DAC were small, therefore we grouped moderate
and severe together. Similarly, moderate or severe CAC were
grouped together.
CVD event rates stratified according to smoking status were
estimated, by dividing the number of CVD events in the
corresponding smoking status category by the number of person-
years at risk in that category.
To assess the relation between current smoking status and CVD
events hazard ratios (HRs) and 95% confidence intervals (95%
CIs) for CVD events were calculated for current smokers, with
former smokers as the reference group. We used a Cox
proportional hazards model with an estimation procedure adapted
for the case-cohort designs. These adaptations were carried out
with the method according to Prentice in which all subcohort
members are equally weighted [12]. Age (continuous), pack years
(continuous), CAC (categorical) and DAC (categorical) were
evaluated for confounding the association of smoking status and
CVD risk.
Smoking and Cardiovascular Calcifications
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Additionally, we performed tests for effect modification by CAC
and DAC by including multiplicative interaction terms with these
variables and smoking status. Analyses were performed with R-
project software package, version 2.15 (www.r-project.org).
Results
During a median follow up of 2.6 years (Q1–Q3, 1.5 to 3.1), 263
CVD events occurred among the 3559 subjects of the baseline
cohort (Table 1), 18 CVD events were fatal and 245 were non-
fatal. The median age subjects experienced a fatal CVD event was
63.3 years and the median age for experiencing a non-fatal CVD
event was 63.1 years. The majority of all CVD events involved
CHD events (54%).
Table 2 presents the baseline characteristics of the CVD cases
and the subcohort. As expected, the cases were slightly older, were
more often current smokers and had more numerous and more
severe cardiovascular calcifications compared to the subcohort.
The number of pack years smoked were comparable among both
groups.
The mean annualized event rate 18.65 events/1000 person
years (95% CI 15.11–22.78) for former smokers versus 26.88
events/1000 person years (95% CI 22.95–31.28) in current
smokers.
In Table 3, unadjusted and adjusted HRs and the 95% CIs for
CVD events are presented for current smokers compared with
former smokers. The unadjusted HR of 1.31 (95% CI 1.03-1.68)
as well as the for age, pack years and cardiovascular calcifications
(CAC and DAC) adjusted HR of 1.33 (95% CI 1.00–1.77) indicate
that there was a statistically significant positive association between
current smoking status and CVD events.
In additional analyses that incorporated multiplicative interac-
tion terms, neither CAC nor DAC modified the association
between smoking status and CVD risk (P= 0.08).
Discussion
In this case cohort study, comprising a population of male
subjects with a long and intense smoking history, followed for a
median period of 2.6 years, we were able to demonstrate that
current smoking behavior was associated with a 31% greater risk
of CVD events compared to former smoking status. This positive
relation remained significant after adjustment for age, number of
pack years and different types of cardiovascular calcifications. The
effect of smoking continuation on CVD risk is identical for all
grades of coronary and aortic calcifications (i.e., no interaction or
effect modification).
Smoking as CVD Risk Factor in Heavy Smokers
Our findings are consistent with previous studies demonstrating
an increased CVD risk among current smokers compared to never
smokers and former smokers [19–21]. Since our study was
conducted in a population comprising subjects with a long and
intense smoking history, our results underline that current smokers
remain to have an increased CVD risk compared to ex-smokers
despite the fact that both groups have a heavy smoking history of
on average 40 pack years. An explanation for this risk difference
could be that smoking increases CVD risk due to multiple
mechanistic pathways with differing temporal responses to
smoking cessation [19–21]. So, on one hand, smoking can causes
irreversible damage, where increased exposure to smoking leads to
more damage and increases CVD risk [9,22]. Smoking has, on the
other hand, potential reversible effects like platelet activation,
Table 1. Specification of the 263 cardiovascular events recorded over a median follow up time of 2.6 year.
Type of cardiovascular event ICD-9/ICD-10 codes Number of events
Non- fatal cardiovascular disease events 245
Coronary heart disease 410–414 137 (56%)
Cerebrovascular disease 430–438 36 (15%)
Other cardiovascular disease 401–405, 420–429, 440–449 72 (29%)
Fatal cardiovascular disease events 18
Coronary heart disease I20–I25 7 (39%)
Cerebrovascular disease I60–I69 3 (17%)
Other cardiovascular disease I30–I52, I70–I79, R00–R09 8 (44%)
doi:10.1371/journal.pone.0066484.t001
Table 2. Baseline characteristics of cardiovascular disease
cases and the subcohort.
Cases Subcohort
n =263 n=341
Age, years 61.4 (57.4–65.8) 60.3 (56.5–64.0)
Pack years, years 38.7 (29.7–49.5) 38.7 (28.0–49.5)
Years of smoking cessation, years 6 (3–10) 5 (2–8)










current smoker 63 58
former smoker 37 42
Follow up time, years 1.4 (0.7–2.1) 2.9 (2.7–3.3)
Values of continuous variables are expressed as median (range) because of non-
normal distribution. Categorical variables are expressed as percentages.
*LAD, Left Anterior Descending.
doi:10.1371/journal.pone.0066484.t002
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coronary spasm and ventricular arrhythmias attributing to the
CVD risk difference between current en ex-smokers [5,20].
Smoking as CVD risk Factor Independent of
Cardiovascular Calcifications
We demonstrated that the effect of current smoking status on
CVD risk is independent of coronary and aortic calcifications. This
finding adds to prior research demonstrating that the absence of
CAC might not be as reassuring in those who smoke, since smokers
without CAC have an increased relative risk of CVD events and all-
cause mortality [23,24]. Factors associated with an increased
relative risk of CVD events in smokers without cardiovascular
calcifications might partly be attributed to the potential presence of
non-calcified plaques, which might be more prone to rupture than
calcified plaques [25]. Furthermore, smoking causes inflammation
of these vulnerable non-calcified plaques [20].
Smoking as well as aortic calcifications have been proposed to
cause an increased CVD risk by the common underlying process
of atherosclerosis [26]. However, we demonstrated that the effect
of current smoking status on CVD risk when jointly modeled with
DAC did not attenuate. This implies that smoking also causes an
increased CVD risk via other mechanisms than the with aortic
calcifications shared atherosclerotic pathway.
Concisely current smoking status exerts its hazardous effects on
CVD risk by pathways that differ from the mechanisms by which
smoking causes cardiovascular calcifications. These findings support
the irreplaceable role of smoking status, for CVD risk evaluation.
Effect Modification of Smoking on CVD Risk by
Cardiovascular Calcifications
Our study as well as previous studies have demonstrated that
smoking as well as coronary and aortic calcifications are considered
to be independent risk factors for CVD, enhancing the possibility for
cardiovascular calcifications tomagnify the adverse effects of current
smoking on CVD risk [26–28]. The present data did not provide
evidence for a potential interaction between current smoking status
with coronary and aortic calcifications. However, in our results the
formal test for interaction was of borderline significance (P= 0.08),
making further investigation in cardiovascular calcifications sub-
groups worthwhile.
Remarks
We used a simple and accurate semi-quantitative assessment
[14] for grading the CAC and DAC on ungated low-dose CT
images. Using low dose scans gives rise to the possibility to miss
extent of small lesions. However, as small calcifications are more
common in those younger than 50 years [29] and as our study
population comprised subjects aged 50 years or older, we do not
expect this phenomenon to have affected our results.
Furthermore, CT scans were performed on 16-slice scanners
with inferior spatial and temporal resolution and subsequently less
accurate assessment of calcifications compared to 64-slice [30].
Similarly, usage of quantitative volume measurements instead of
semi-quantitative assessments gives a more precise quantification
of the cardiovascular calcifications. Though, if this would lead to a
better prediction of the attenuation of the CVD risk estimates by
cardiovascular calcifications is debatable. Ongoing studies are
investigating the replacement value of automatic quantitative
measurements of the coronary arteries and aorta calcifications by
semi-quantitative assessments.
In addition, we have limited the visual grading to calcifications in
the left anterior descending coronary artery and descending aorta.
Sowe cannot be sure if current smoking exerts its hazardous effect on
CVD risk independent of calcifications in the whole coronary tree or
aorta. Although, we can expect this relation to be true as the CAC
distribution in the coronary tree reflects the natural history of the
disease, starting at the first 2 cm of the left anterior descending
coronary artery, followed by the right coronary artery, left main and
left circumflex coronary artery (LCX) [31] thereby verifying
previous pathological anatomic studies [32] and analysis of coronary
angiography [33]. It has also been demonstrated that calcifications
in the descending aorta, in particular, aremore dominant in all CVD
events compared with ascending aorta calcifications and both
ascending and descending aorta calcifications [8].
Moreover, the data on smoking status originates from self-
completed questionnaires without biochemical verification of the
smoking status, with the risk of social desirability response bias.
However, self-reports on smoking behavior appeared to be valid in
a lung cancer screening setting [34].
Study Limitations
One of the shortcomings of this study is the limited general-
izability of the outcomes because this study was conducted in a
male lung cancer screening population of current or former
smokers with a smoking history .16.5 pack years. We cannot be
sure that current smokers with a smoking history ,16.5 pack
years, female gender or individuals who receive a chest-CT for
other reasons than lung cancer screening have an increased CVD
risk of 33% compared to ex-smokers.
Another potential weakness is that smoking status is determined
at baseline and treated as a time-independent factor, i.e. not
changing in time. Dichotomizing smoking status can be subopti-
mal since it is likely that someone who stopped smoking at baseline
and restarts smoking during follow up (i.e., mixed smoking history)
is suspected to be at a higher CVD risk than a person who remains
a quitter. This nondifferential misclassification that could arise
over time may dilute the difference in CVD risk between ex and
current smokers, resulting in an underestimation of the true HR.
However, a review on the magnitude of risk reduction achieved by
Table 3. CVD event HRs and 95% CIs in current smokers as compared with former smokers.
HR (95% CI) for current smoker
Crude 1.31 (1.03–1.68)
*Age and pack years adjusted 1.48 (1.12–1.97)
{Age, pack years, CAC ` and DAC1 calcification adjusted 1.33 (1.00–1.77)
*Adjusted for age (continuous) and pack years (continuous).
{Adjusted for age (continuous), pack years (continuous), Left Anterior Descending.
`Coronary Artery Calcifications(3 categories),
1Descending Aorta Calcifications (3 categories).
doi:10.1371/journal.pone.0066484.t003
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smoking cessation in patients with CHD showed that the risk
reduction reported in studies excluding patients who reported
mixed smoking histories did not statistically differ from studies that
did not account for this misclassification [35]. Furthermore,
collecting reliable data on smoking is challenging and many
prognostic models like the Framingham [36] and PROCAM [37]
risk score have been developed with smoking as a time
independent factor.
Additionally in observational research, like in our case cohort
study, unobserved confounding could be a source of bias [38].
Since good life style behavior appear to cluster, e.g. persons who
quit smoking appear to have higher rates of diet and exercise
modifications that effectively lower CVD [39], there is always the
chance that the reduced CVD risk among ex-smokers we observed
was due to unmeasured health attitudinal characteristics inherent
to smoking cessation.
Conclusions
Current smoking status remains an important CVD event risk
factor even in a population of heavy smokers. Current smoking
exerts its hazardous effects on CVD risk by pathways independent
of cardiovascular calcifications. These findings support the
irreplaceable role of smoking status, for CVD risk evaluation.
Our data reinforce the notion that all current smokers, including
those with a heavy smoking history and those with and without
cardiovascular calcifications, should be encouraged to quit.
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